[Clinical study of veralipride in menopausal sudden flushes (author's transl)].
A double-blind clinical study was conducted to compare the therapeutic activity of veralipride and placebo in menopausal sudden flushes. Comparison of final numerical rate showed a statistical significant superiority for veralipride. Tolerance was excellent and no significant difference was observed between clinical side effects, or biological parameters studied (blood counts and differential, and blood bilirubin, transaminases, glucose, cholesterol, or creatinine levels) in the two groups.
D000328:Adult; D001772:Blood Cell Count; D002979:Climacteric / Q000187:drug effects*; D002986:Clinical Trials as Topic; D003404:Creatinine / Q000097:blood; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008593:Menopause / Q000187:drug effects; D008875:Middle Aged; D013469:Sulpiride / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D000637:Transaminases / Q000097:blood
D013469:Sulpiride; D003404:Creatinine; D000637:Transaminases; C027429:veralipride
Etude du véralipride dans le traitement des bouffées de chaleur de la ménopause.